ON Partners, over the last few years, has collaborated with Niche and its CEO to grow its executive leadership team.
Spruce Biosciences Appoints Chief Medical Officer
Spruce Biosciences, a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, has appointed Dr. Rosh Dias to Chief Medical Officer. The appointment coincides with progress into Phase 2b clinical trials of tildacerfont in adult classic congenital adrenal hyperplasia (CAH).
“We are thrilled that Rosh is bringing to Spruce his strong industry and operational leadership experience as we advance our Phase 2b clinical trials of tildacerfont in CAH, and prepare to initiate Phase 2 clinical trials of tildacerfont in pediatric classic CAH and polycystic ovary syndrome in 2021,” said Richard King, Chief Executive Officer of Spruce Biosciences. “Rosh has deep experience in successful clinical development and commercialization of important treatments for patients with rare diseases, which will prove critical for our clinical development and registration strategies. Throughout his career, Rosh has shaped the understanding of novel treatments and their application, which will complement the capabilities of our existing team.”
Dr. Dias will oversee global clinical strategy and development for the company. He brings more than 20 years of experience in the pharmaceutical and biotechnology industries across multiple geographies, working to commercialize medicines for patients across multiple therapeutic areas, including the achievement of blockbuster status for several medicines. Dr. Dias joins Spruce most recently from Indivior, where he was the Chief Medical Officer for the past year. Prior to Indivior, Dr. Dias has had long tenures at both Amgen and Novartis. At Amgen, he was Vice President of Global Scientific Affairs, leading global scientific affairs spanning Amgen’s entire product portfolio and Vice President, Head of Global Medical and Scientific affairs at Onyx. Prior to Onyx, Dr. Dias spent a decade in various roles for Novartis, including senior Clinical Development and Medical Affairs roles in both the United States and Australia, where he led a variety of clinical development and medical affairs efforts with a focus on oncology, hematology, and rare diseases. Dr. Dias holds a Medical Doctor degree from Charing Cross and Westminster Medical School in the UK, and is a Member of the Royal College of Physicians through postgraduate qualification in Internal Medicine.
“I’m excited to join Spruce at this time of important growth and evolution for the company,” said Dr. Dias. “Spruce is a leader in the investigation of medicines in the field of rare endocrine disorders and has rapidly advanced tildacerfont into late-stage clinical development. I am pleased to work together with our experienced management team on the development of tildacerfont in adult classic CAH and other indications in our pipeline.”
Read the full press release published by Spruce Biosciences here.
ON Partners consultant Suzanne Zebedee, Ph.D. is proud to have partnered with Spruce Biosciences and Dr. Dias on this successful placement. For more executive search work in Life Sciences, visit our recent successful placements here.
ABOUT SPRUCE BIOSCIENCES
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. The company has initiated a placebo-controlled, double-blind Phase 2b clinical trial in adult patients with classic CAH with poor disease control and anticipates topline results in the fourth quarter of 2021. The company also initiated a second placebo-controlled, double-blind Phase 2b clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipates topline results in the first half of 2022. The company also plans to evaluate tildacerfont in pediatric classic CAH and polycystic ovary syndrome. For more information, please visit www.sprucebiosciences.com.
ABOUT ON PARTNERS
ON Partners propels an organization’s mission by building C-level and board leadership teams. Founded in 2006 by like-minded consultants as a values-driven alternative to the multi-service global firms they were leaving behind, ON delivers a better executive search experience. Named by Forbes as one of America’s Best Executive Recruiting Firms and to the Inc. 500/5000 Lists seven times, the firm is consistently ranked among the top 20 retained executive search firms in the U.S. For more information, see our results here.
Follow our work, updates and recent success on Twitter and LinkedIn.
Find our related successful placements of leading executives here.
About ON Partners
Since 2006, ON Partners is the only pure-play executive search firm building diverse C-level and board leadership teams. We rebuilt the institution of executive search for the way you work. Our approach includes present partners who engage with their clients from the first brief to the final decision, individually crafted solutions that are unique to each client, and an easier experience all around. Named by Forbes as one of America’s Best Executive Recruiting Firms and to the Inc. 500/5000 Lists nine times, ON Partners is consistently ranked among the top 20 retained executive search firms in the U.S.
Untraditional by Choice. Original by Design. Since 2006.
START YOUR JOURNEY WITH US TODAY.
If you want to create a new path – ON Partners knows how to help you get there.